NASDAQ:ACXP
Acurx Pharmaceuticals, Inc.
Acurx Pharmaceuticals, Inc. reported net income of −$8.0M in fiscal 2025. The diluted share count rose 85.5%.Summary generated from Acurx Pharmaceuticals, Inc.'s SEC filings. Latest annual report filed Mar 12, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)n/a
Revenue growthn/a
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating marginn/a
Net marginn/a
ROICn/a
Return on equity−270.8%
Debt / equityn/a
Free cash flown/a
FCF marginn/a
Share count change+85.5%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | n/a | n/a | n/a | n/a | n/a |
| Operating income | n/a | n/a | n/a | −14 | −8 |
| Net income | −13 | −12 | −15 | −14 | −8 |
| Free cash flow | n/a | n/a | n/a | n/a | n/a |
Recent filings
- S-1Registration statement
Sep 8, 2026 - DEF 14AProxy statement
Sep 1, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 13, 2026 - 10-QQuarterly report for the period ended Mar 31, 2026
May 11, 2026 - S-1Registration statement
May 4, 2026 - S-1Registration statement
May 4, 2026 - 4Insider transaction report
Apr 22, 2026 - 4Insider transaction report
Apr 22, 2026